Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

Introduction Mood disorders are frequent in Parkinson’s disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on N...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2021-10, Vol.38 (10), p.5398-5411
Main Authors: Labandeira, Carmen M., Alonso Losada, Maria G., Yáñez Baña, Rosa, Cimas Hernando, Maria I., Cabo López, Iria, Paz González, Jose M., Gonzalez Palmás, Maria J., Martínez Miró, Cristina, Santos García, Diego
Format: Article
Language:English
Subjects:
Aged
Alanine - analogs & derivatives
Alanine - therapeutic use
Benzylamines - therapeutic use
Cardiology
Endocrinology
Female
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Research
Parkinson Disease - drug therapy
Pharmacology/Toxicology
Prospective Studies
Rheumatology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Mood disorders are frequent in Parkinson’s disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in patients with Parkinson’s disease) study. Methods SAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. Patients with PD were required to have at baseline a Non-Motor Symptoms Scale (NMSS) total score of at least 40. In this analysis, the changes from V1 (baseline) to V4 (6 months ± 1 month) in the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson’s Disease Questionnaire-39) emotional well‐being domain were analyzed. Depression was identified and classified (DSM-IV and Judd criteria) at baseline and at the end of follow-up as major depression (MD), minor depression (mD), subthreshold depression (subD), and non-depression (nonD). Results Fifty patients with PD were included (age 68.5 ± 9.12 years; 58% women; 6.4 ± 5.1 years from diagnosis) and 44 patients (88%) completed the follow-up at 6 months. The BDI-II total score was reduced by 35.9% (from 15.88 ± 10.46 at V1 to 10.18 ± 6.76 at V4; p  
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-021-01873-w